ClinicalTrials.gg
CompletedNCT00425256Updated Feb 23, 2011

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

A Phase 2 interventional study of Bremelanotide in Sexual Arousal Disorder, sponsored by Palatin Technologies, Inc. Completed at 20 sites in United States. Open to female participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-02-23.

Sponsored by Palatin Technologies, Inc · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.

Started
2006
with 6 others
Phase 2
13 of 62
1 open now
Registered
14th of 62
by date
Lead sponsor
4 of 62
Palatin Technologies, Inc

Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is one of 7 that started in 2006, is one of 13 in phase 2, and was the 14th registered.

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

Browse Sexual Dysfunctions, Psychological studies →

Open to participants now

3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 21 Years to 70 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Sexual Dysfunctions, Psychological with a site in United States, or all of them as a file.
02

Study summary

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

03

Conditions studied

  • Sexual Arousal Disorder
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
Female

Eligibility criteria

Inclusion Criteria:

  • Post menopausal and in general good health
  • In a stable relationship with a male partner for at least 6 months
  • Willing to attempt sexual activity once a week with your partner
05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

06

Study locations

20 sites
  • Medical Affiliated Research Center
    Huntsville, Alabama, United States
  • Quality of Life Medical & Research Center, LLC
    Tucson, Arizona, United States
  • University of California, Department of Family and Preventative Medicine
    LaJolla, California, United States
  • Downtown Women's Health Care
    Denver, Colorado, United States
  • Coastal Connecticut Research
    New London, Connecticut, United States
  • South Florida Medical Research
    Aventura, Florida, United States
  • Clinical Study Center
    Ft. Myers, Florida, United States
  • Center For Marital and Sexual Health of South Florida
    West Palm Beach, Florida, United States
  • Northeast Indiana Research
    Fort Wayne, Indiana, United States
  • Center for Sexual Medicine at Sheppard Pratt
    Baltimore, Maryland, United States
  • Advanced Biomedical Research, Inc
    Hackensack, New Jersey, United States
  • The Center for Female Sexuality
    Purchase, New York, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina, United States
  • Lyndhurst Gynecologic Associates
    Winston-Salem, North Carolina, United States
  • The Ohio State University
    Columbus, Ohio, United States
  • Medford Women's Clinic, LLP
    Medford, Oregon, United States
  • Clinical Trials Research Services, LLC
    Pittsburgh, Pennsylvania, United States
  • Advanced Clinical Therapies, Inc.
    West Reading, Pennsylvania, United States
  • Accelovance
    Houston, Texas, United States
  • Women's Clinical Research Center
    Seattle, Washington, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2007
First posted
Jan 22, 2007
Start
Feb 2006
Primary completionActual
May 2007
CompletionActual
May 2007
Last update
Feb 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00425256
Lead sponsor
Palatin Technologies, Inc
Collaborators
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
First posted
Jan 22, 2007
Start date
Feb 2006
Primary completion
May 2007
Completion
May 2007
Last update
Feb 23, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bremelanotide

Start the discussion